SANDIMMUNE
LOE ApproachingNDAORALSOLUTIONPriority Review
Approved
Nov 1983
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
3/8 — Basic
Priority Review
SANDIMMUNE by Novartis is clinical pharmacology mechanism of action cyclosporine is a potent immunosuppressive agent, which in animals prolongs survival of allogeneic transplants involving skin, heart, kidney, pancreas, bone marrow, small intestine, and lung. First approved in 1983.
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SANDIMMUNE (cyclosporine) is a potent immunosuppressive small molecule that selectively inhibits T-lymphocyte activation and proliferation by blocking interleukin-2 production. It is indicated for organ transplant recipients to prevent allograft rejection. The drug works by reversibly suppressing cell-mediated immunity while sparing bone marrow and phagocytic function.
LOE Approaching
Product is approaching loss of exclusivity; commercial team likely focused on defending market share and managing transition to generic erosion.
Mechanism of Action
CLINICAL PHARMACOLOGY Mechanism of Action Cyclosporine is a potent immunosuppressive agent, which in animals prolongs survival of allogeneic transplants involving skin, heart, kidney, pancreas, bone marrow, small intestine, and lung. Cyclosporine has been demonstrated to suppress some humoral…
Worked on SANDIMMUNE at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.